Maternal obesity and the metabolic syndrome in reproductive health: assessing incretin-based interventions
Open Access
- 19 May 2026
- journal article
- review article
- Published by Springer Nature in Reviews in Endocrine and Metabolic Disorders
- Vol. 27 (4) , 1-22
Abstract
The global epidemic of overweight and obesity threatens gynecological and reproductive health, necessitating effective therapeutic strategies to improve maternal and fetal long-term health outcomes. This review provides an overview of weight loss interventions and discusses their use in the context of gestation, such as surgical interventions and anti-obesity medications. As the interest in incretin-based therapies has risen substantially, we discuss how incretin-based therapies, including glucagon-like peptide-1 (GLP-1) receptor agonists and GLP-1 receptor agonists and glucose-dependent insulinotropic polypeptide (GIP) dual agonists, might improve reproductive function and could interact with the physiological metabolic changes ensuring a healthy pregnancy. These metabolic adaptations during pregnancy arise from the integration of insulin signaling, lipid metabolism, placental endocrine function, mitochondrial remodeling and inflammatory regulation. Furthermore, we consider not only short-term consequences of maternal overweight and obesity but also focus on fetal long-term health trajectories following pregnancy-related metabolic disorders, as maternal obesity and gestational weight gain are considered risk factors for childhood obesity and overweight.Keywords
Funding Information
- Universitätsklinikum Hamburg-Eppendorf (UKE)
This publication has 198 references indexed in Scilit:
- Gestational Weight Gain and Pregnancy Outcomes After GLP-1 Receptor Agonist DiscontinuationJAMA, 2025
- Increasing Postpartum Use of GLP-1 Receptor AgonistsJAMA, 2025
- Safety of GLP-1 Receptor Agonists and Other Second-Line Antidiabetics in Early PregnancyJAMA Internal Medicine, 2024
- Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With ObesityJAMA, 2024
- Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without DiabetesJAMA, 2022
- Management of prepregnancy, pregnancy, and postpartum obesity from the FIGO Pregnancy and Non‐Communicable Diseases Committee: A FIGO (International Federation of Gynecology and Obstetrics) guidelineInternational Journal of Gynecology & Obstetrics, 2020
- Effect of Naltrexone-Bupropion on Major Adverse Cardiovascular Events in Overweight and Obese Patients With Cardiovascular Risk FactorsJAMA, 2016
- The Effectiveness and Risks of Bariatric SurgeryJAMA Surgery, 2014
- Management of suspected anastomotic leak after bariatric laparoscopic Roux-en-y gastric bypassBritish Journal of Surgery, 2014
- Effects of Diet and Physical Activity Interventions on Weight Loss and Cardiometabolic Risk Factors in Severely Obese AdultsJAMA, 2010